GLP-1 Drugs and Asthma Risk: Read the Severity Column, Not the Headline

A cohort study of people with type 2 diabetes reported that those taking a GLP‑1 were less likely to develop asthma, with an adjusted hazard ratio of 0.67.^[1] Read one row further and the picture gets more complicated. The association was strongest for the mildest asthma and weakest for the most severe, and at the severest endpoint of all, cases requiring a breathing tube, it vanished. That pattern deserves more of your attention than the headline number.

What the study found

Researchers used Taiwan’s National Health Insurance database from 2011 to 2015, excluding anybody who already had asthma. Out of a cohort of 1,936,512 people with type 2 diabetes, 1,345 were treated with a GLP‑1 receptor agonist. Mean follow-up was 2.92 years.^[1]

The authors describe this as a protective trend across severity levels, except in cases requiring intubation. That is accurate, but the same column also reads as a gradient that weakens steadily the sicker the endpoint gets, until at the top it is indistinguishable from no effect at all.

What 1,345 people means

The exposed group is 1,345 out of nearly two million. New-onset asthma in adults with diabetes is uncommon, so the number of asthma cases inside that exposed group will be small, and the confidence intervals reflect it. However large the database, the drug arm here is smaller than many single-center trials.

The years matter too. The paper gives its study period as January 1, 2011 to December 31, 2015,^[1] two years before the FDA first approved semaglutide, in December 2017,^[2] and well before tirzepatide. Yet its table of results by individual drug includes a semaglutide subgroup.^[1] The paper does not explain how, so the per-drug results are hard to interpret. For the drugs most people are prescribed today, the authors’ suggestion of a class effect remains an inference.

And COPD, where the studies are observational

COPD is usually paired with asthma when this question is raised. It has its own records, and the asthma result cannot stand in for them. A US insurance-claims study of people with COPD and type 2 diabetes matched 32,107 pairs and found fewer moderate or severe flare-ups after starting a GLP‑1 than after starting a DPP‑4 inhibitor, with a hazard ratio of 0.86, over a median of 145 days on treatment.^[3] A 2025 review of flare-ups in people with both conditions pooled nine observational studies and retrieved no randomized trials.^[4] The comparison drug matters: against metformin, a Japanese cohort found no clear difference (hazard ratio 1.07, 95% CI 0.87–1.32).^[5]

The one randomized trial we found in COPD gave 40 people with obesity liraglutide 3.0 mg or placebo for 40 weeks and measured lung function, not flare-ups. Forced vital capacity and symptom scores improved; FEV1 and walking distance did not change significantly.^[6]

What to do with it

• No GLP-1 is approved to prevent or treat asthma, and nothing here suggests taking one for that reason.
• This is a single retrospective cohort with 1,345 exposed people and no randomization.
• The severity gradient runs in the direction that confounding would produce, which is the main reason to hold the result loosely.
• If you have asthma and are considering a GLP-1 for weight or diabetes, this is not a reason for concern either, since the study found no signal of harm.
• Inhaled therapy is not something to change on the strength of a records study. That is a conversation with whoever manages your asthma.

For the airway condition where a GLP‑1 does hold an approved indication and a randomized trial, see Zepbound for sleep apnea.